Sharon Chandler, NP
Pediatrics · Farmville, VANPI 1427036649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 35.0% of the total. Among pediatrics clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$723
- Pfizer$714
- AstraZeneca$417
- Lilly USA, LLC$256
- Biohaven Pharmaceutical Holding Company Ltd.$242
- plus $1K from 25 others
What the payments were for
- Food & beverage$5,67199%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 134 | $2,010 |
| Novo Nordisk | 36 | $723 |
| Pfizer | 52 | $714 |
| AstraZeneca | 15 | $417 |
| Lilly USA, LLC | 14 | $256 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $242 |
| Bayer | 7 | $207 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $194 |
| Organon | 9 | $160 |
| Amgen | 9 | $119 |
| Abbott | 5 | $109 |
| Astellas Pharma US Inc | 2 | $85 |
| Dexcom, Inc. | 4 | $77 |
| Merck | 4 | $58 |
| Boston Scientific | 1 | $57 |
| Exact Sciences | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Indivior Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Heartflow, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Scynexis, Inc. | 1 | $15 |
| Metacel Pharmaceuticals LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,739 in reported general payments places this provider in the 95th percentile of 1,542 pediatrics providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 38 | $40,482 |
| FarxigaDapagliflozin Propanediol | 32 | $27,673 |
| OzempicSemaglutide | 27 | $23,751 |
| XareltoRivaroxaban | 29 | $23,660 |
| EliquisApixaban | 28 | $19,767 |
| JardianceEmpagliflozin | 19 | $16,689 |
| TrulicityDulaglutide | 14 | $16,669 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $16,072 |
| MyrbetriqMirabegron | 14 | $9,930 |
| Emgality PenGalcanezumab-Gnlm | 13 | $9,032 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,409 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,425 |
| VeozahFezolinetant | 11 | $5,747 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,175 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $58 | $56,55460 claims |
| AstraZenecaFarxiga | $417 | $27,67332 claims |
| Novo NordiskOzempic | $723 | $23,75127 claims |
| Johnson & JohnsonXarelto | $19 | $23,66029 claims |
| PfizerEliquis | $714 | $19,76728 claims |
| Lilly USA, LLCTrulicity | $256 | $16,66914 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $85 | $15,67725 claims |
| GSKTrelegy Ellipta | $17 | $8,40913 claims |
| AbbVieSynthroid | $2,010 | $1,32412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,542 pediatrics providers in Virginia.
Other pediatrics in Farmville
- Patricia MulreanyMidlothian$1.5M
- Dominick PastoreRichmond$1.1M
- Judith GrossbergMidlothian$291K
- Elizabeth CullenMidlothian$289K
- Martha SaundersMidlothian$288K
- Anne Marie IraniRichmond$265K
- Ozlem Goker-AlpanFairfax$210K
- Tamara SutherlandGlen Allen$145K
- Tamara Charity-BrownPetersburg$145K
- Alan RogolCharlottesville$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.